NorthEdge, a middle-market private equity firm that provides capital and management solutions to companies in the North of England, completed the investment in Antibody Analytics, a developer of bioassays designed to support biopharmaceutical development. Financial terms were not disclosed. "This marks a watershed moment for Antibody Analytics. We're committed to using this investment as a tool – to create jobs, expand our facilities, solidify our global standing and allow us to realise our vision of a healthier future for all," Andy Upsall, Antibody Analytics CEO.